EyePoint, Inc. 8-K

What Happened

• On May 14, 2026, EyePoint, Inc. announced a positive recommendation from the independent Data Safety Monitoring Committee (DSMC) following completion of the third scheduled review of its ongoing pivotal Phase 3 program evaluating DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD). The company filed an 8-K and attached a press release dated May 14, 2026.

Key Details

• Drug/program: DURAVYU™ — pivotal Phase 3 program for wet AMD.
• Review: Positive DSMC recommendation after the third scheduled safety/efficacy review.
• Filing: 8-K (Item 8.01 Other Events) filed May 14, 2026; press release included as Exhibit 99.1.
• Signature on the filing: George O. Elston, Executive VP & CFO.

Why It Matters

• A positive DSMC recommendation is a material clinical milestone: it indicates the independent committee did not identify issues at this scheduled review and supports continued conduct of the Phase 3 program.
• For investors, this reduces near-term clinical risk around safety reviews and is a constructive development for DURAVYU’s clinical progression and eventual regulatory prospects.
• The 8-K does not provide new financial results or timing updates for trial completion or regulatory submissions; investors should watch for company updates with top-line or enrollment milestones.